Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Jay McLean (1890-1957), discoverer of heparin.JAMA. 1967; 201: 770
- The discovery of dicumarol and its sequels.Circulation. 1959; 19: 97-107
- American College of Chest Physicians. New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th edition: American College of Chest Physicians evidence-based clinical practice guidelines.Chest. 2012; 141: e120S-e151S
- Hétérogénéité pharmacologique des nouveaux anticoagulants.J Mal Vasc. 2011; 36: S10-S15
- Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban – an oral, direct factor Xa inhibitor – are not affected by aspirin.J Clin Pharmacol. 2006; 46: 981-990
- Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip of knee arthroplasty.Thromb Res. 2011; 130: 147-151
- Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomized, double-blind, phase II trial.Lancet. 2009; 374: 29-38
- Effect of hepatic impairment on the pharmacodynamics and tolerability of rivaroxaban – an oral, direct factor Xa inhibitor.J Thromb Haemost. 2007; 5: 635
- Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.N Engl J Med. 2008; 358: 2765-2775
- Extended duration rivaroxaban versus short term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double blind, randomised controlled trial.Lancet. 2008; 372: 31-39
- Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.N Engl J Med. 2008; 358: 2776-2786
- Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty: a randomised trial.Lancet. 2009; 373: 1673-1680
- Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.N Engl J Med. 2011; 365: 883-891
- Rivaroxaban – once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study.Am Heart J. 2010; 159: 340-347
- A dose-ranging study evaluating once daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study.Blood. 2008; 112: 2242-2247
- Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (Einstein-extension study).Expert Rev Cardiovasc Ther. 2011; 9: 841-844
- Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.N Engl J Med. 2012; 366: 1287-1297
- MAGELLAN Steering Committee. Rivaroxaban for thromboprophylaxis in acutely ill medical patients.N Engl J Med. 2013; 368: 1945-1946
- Rivaroxaban in patients with a recent acute coronary syndrome.N Engl J Med. 2012; 366: 9-19
- In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition and induction studies.Drug Metab Dispos. 2009; 38: 448-458
- Apixaban or enoxaparin for thromboprophylaxis after knee replacement.N Engl J Med. 2009; 361: 504-604
- Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomized double-blind trial.Lancet. 2010; 375: 807-815
- Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.N Engl J Med. 2010; 363: 2487-2498
- Apixaban in patients with atrial fibrillation (AVERROES Study).N Engl J Med. 2011; 364: 806-817
- Apixaban versus warfarin in patients with atrial fibrillation.N Engl J Med. 2011; 365: 981-992
- Oral apixaban for the treatment of acute venous thromboembolism.New Engl J Med. 2013; 369: 799-808
- Apixaban for extended treatment of venous thromboembolism.N Engl J Med. 2013; 368: 699-708
- A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer.J Thromb Haemost. 2012; 10: 807-814
- Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.N Engl J Med. 2011; 365: 2167-2177
- Apixaban with antiplatelet therapy after acute coronary syndrome.N Engl J Med. 2011; 365: 699-708
- Edoxaban: a new oral direct factor Xa inhibitor.Drugs. 2011; 71: 1503-1526
- Edoxaban versus warfarin in patients with atrial fibrillation.New Engl J Med. 2013; 369: 2093-2104
- Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.New Engl J Med. 2013; 369: 1406-1415
- Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitors.Bioorg Med Chem Lett. 2009; 19: 2179-2185
- A randomized evaluation of betrixaban an oral factor Xa inhibitor for prevention of thromboembolism events after total knee replacement (EXPERT).Thromb Haemost. 2009; 101: 68-76
- Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2 randomized dose-ranging study (EXPLORE-Xa).Eur Heart J. 2013; 34: 1498-1505
- Laboratory assessment of new anticoagulants.Clin Chem Lab Med. 2011; 49: 761-772
- Deux nouveaux anticoagulants: dabigatran et Rivaroxaban. Leur impact sur les examens de laboratoire.Biotribune. 2011; 38: 16-21
- Nouveaux anticoagulants par voie orale: quelle place pour les analyses de biologie médicale?.Sang Thrombose Vaisseaux. 2011; 23: 8-17
- Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban.Thromb Res. 2012; 129: 101-103
- Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide.Thromb Haemost. 2013; 110: 283-294
- The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study.J Thromb Haemost. 2011; 9: 226-228
- Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor.Thromb Haemost. 2010; 103: 815-825
- Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement.Thromb Res. 2011; 127: 457-465
- Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study.J Thromb Thrombolysis. 2013; 35: 140-146
- Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial.Clin Appl Thromb Hemost. 2012; 18: 150-158
- Evaluation of the anti-Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls.Thromb Haemost. 2012; 107: 379-387
- Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study.Thromb Haemost. 2014; 111: 240-248
- An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma.Thromb Haemost. 2010; 104: 1078-1079
- Questions-réponses sur l’utilisation du rivaroxaban dans le traitement de la maladie thromboembolique veineuse.J Mal Vasc. 2012; 37: 300-310
- Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery.Thromb Haemost. 2012; 108: 887-895
- Surgery and invasive procedures in patients on long-term treatment with oral direct thrombin or factor Xa inhibitors.Ann Fr Anesth Reanim. 2011; 30: 645-650
- Accidents hémorragiques des nouveaux anticoagulants.J Mal Vasc. 2013; 38: 259-270
- Dabigatran, a direct thrombin inhibitor, can be a life-saving treatment in heparin-induced thrombocytopenia.ARYA Atheroscler. 2013; 9: 112-114
- Nonheparin anticoagulants for heparin-induced thrombocytopenia.N Engl J Med. 2013; 368: 2333-2334
Article info
Publication history
Published online: July 25, 2014
Footnotes
Disclosure: M.M. Samama has received research grants, consulting fees as a member of advisory boards, and speaker and/or investigator fees from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb (BMS), Daichii Sankyo, GlaxoSmithKline (GSK), Pfizer, Rovi, and Sanofi. S. Meddahi discloses no conflict of interest. C.M. Samama has received research grants, consulting fees as a member of advisory boards, and speaker and/or investigator fees from Abbott, AstraZeneca, Baxter, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb (BMS), CSL Behring, Daiichi Sankyo, Fresenius-Kabi, GlaxoSmithKline (GSK), Haemonetics, Laboratoire Français du Fractionnement et des Biotechnologies (LFB), Lilly, Novo Nordisk, Pfizer, Rovi, and Sanofi.
Identification
Copyright
© 2014 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
